PURPOSE
COPE evaluated serial circulating tumor DNA (ctDNA) profiling with molecular tumor board (MTB) review during first-line therapy for advanced non-small cell lung cancer (NSCLC).
EXPERIMENTAL DESIGN
COPE was a multicenter, randomized (2:1), noncomparative phase II trial. Arm A underwent serial plasma profiling...
Candice Francheska B. Tambaoan, Letuan Phan, S. Cousin et al.· Clinical Cancer Research· 0 citations
Background There is no standard second-line treatment for patients with platinum refractory advanced B3-Thymoma (T) and thymic carcinoma (TC). In this population, the PECATI trial testing lenvatinib plus pembrolizumab met its primary endpoint, with 5-month progression-free survival (PFS) of 88.0% (90% CI: 73.5–94.8). M...
Jordi Remon, Paolo Bironzo, Nicolas Girard et al.· Mediastinum· 0 citations
It is shown that spatial CD8+ T-cell exclusion is associated with lower objective response rates and shorter progression-free survival in ICB-treated NSCLC patients, and further evaluation of spatial immune contexture as a complementary biomarker in ICB-treated patients is supported.
J. Guégan, B. Bonhomme, F. Peyraud et al.· Signal Transduction and Targ...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.